S1P Receptor Modulators For Treating Multiple Sclerosis

Patent No. EP2959894 (titled "S1P Receptor Modulators For Treating Multiple Sclerosis") was filed by Novartis on Jun 25, 2007. The application was issued on Oct 12, 2022.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (23)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2959894

NOVARTIS
Application Number
EP15177166A
Filing Date
Jun 25, 2007
Status
Granted And Under Opposition
Sep 9, 2022
Publication Date
Oct 12, 2022